V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160012411 | 160008888 | 1.8 | 83.6 | Palliative (P) | 2019-01-21 | 2019-02-19 | GemCarbo Days 1+8 | 02 | N | IVADO | 101722548 |
| 160012451 | 160008889 | null | null | Palliative (P) | 2017-09-17 | 2017-10-07 | CARBOPLATIN | 02 | null | CARBOPLATIN | 100650732 |
| 160012455 | 160008890 | 1.65 | 78.6 | Palliative (P) | 2017-05-26 | 2017-06-11 | Doxorubicin + Olaratumab | 02 | null | EW EUROEWING 2012 ARM B VDC | 100067373 |
| 160012508 | 160008891 | 1.72 | 75 | Palliative (P) | 2017-07-20 | 2017-07-28 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101725504 |
| 160012675 | 160008892 | null | 75.6 | Palliative (P) | 2019-10-18 | 2019-10-18 | CHOP | 01 | null | TRIAL UNSPECIFIED | 100814415 |
| 160012688 | 160008893 | 1.52 | 57.5 | null | 2019-06-05 | 2019-06-07 | CARBOPLATIN + PACLITAXEL | N | N | CARBOPLATIN + PACLITAXEL | 100989511 |
| 160012721 | 160008894 | 1.8 | 77 | Curative (C) | 2013-06-20 | 2013-07-04 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101777446 |
| 160012758 | 160008895 | 1.51 | 52.2 | Neo-adjuvant (N) | null | 2015-06-11 | Carboplatin + Paclitaxel (weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100056677 |
| 160012860 | 160008896 | 1.78 | 78.35 | Neo-adjuvant (N) | 2019-04-20 | 2019-04-21 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100453526 |
| 160012971 | 160008897 | 1.71 | 92 | Palliative (P) | 2019-03-05 | 2019-03-19 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101093513 |
| 160013122 | 160008898 | 1.82 | 69.3 | Palliative (P) | 2019-08-19 | 2019-09-30 | Bevacizumab+Carbo+Pacliaxel | 02 | N | PACLITAXEL | 100659814 |
| 160013155 | 160008899 | null | null | null | 2018-12-30 | 2019-01-01 | ETOP 13-18 BEAT-meso Trial | 02 | null | DOXORUBICIN + OLARATUMAB | 101754107 |
| 160013221 | 160008900 | 1.79 | 112 | Palliative (P) | null | 2019-07-30 | Carboplatin AUC 6 - 10 | N | null | CARBOPLATIN | 101369553 |
| 160013237 | 160008901 | 1.53 | 49.4 | Palliative (P) | 2016-06-11 | 2016-06-23 | Doxorubicin + Olaratumab | 02 | N | DOXORUBICIN + OLARATUMAB | 100446913 |
| 160013461 | 160008904 | 1.7 | 109.8 | Palliative (P) | 2017-10-25 | 2017-11-14 | VIDE | 02 | N | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 101452805 |
| 160013479 | 160008905 | 1.77 | 63.55 | Palliative (P) | 2019-12-13 | 2019-12-16 | Liposomal Doxorubicin (Caelyx) | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100037693 |
| 160013499 | 160008906 | 1.76 | 75 | Palliative (P) | 2018-10-12 | 2018-10-12 | Ifosfamide + Liposomal Doxorubicin | N | N | IVA | 100104603 |
| 160013663 | 160008907 | null | null | Palliative (P) | 2021-09-07 | 2021-09-07 | DOXORUBICIN | 02 | null | LIPOSOMAL DOXORUBICIN | 101502334 |
| 160013780 | 160008908 | 1.65 | 40 | Palliative (P) | 2018-04-07 | 2018-04-16 | Doxorubicin + Olaratumab | 02 | N | DOXORUBICIN | 100980541 |
| 160013823 | 160008909 | null | 57.9 | 03 | 2018-08-18 | 2018-09-01 | Doxorubicin 75mg/m2 | N | N | NB HRNBL-1 COJEC IND COURSE A | 100545757 |
| 160013993 | 160008910 | 1.74 | 79 | Palliative (P) | 2019-06-07 | 2019-06-22 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101743858 |
| 160014086 | 160008911 | 1.78 | 75.2 | Palliative (P) | 2018-04-23 | 2018-04-24 | Dox + HD Mtx (post PAM) | null | N | DOXORUBICIN + IFOSFAMIDE | 100998920 |
| 160014131 | 160008912 | 1.54 | 68.7 | null | 2016-12-13 | 2016-12-17 | IVADo | null | N | EW EUROEWING 2012 ARM B VDC | 101216764 |
| 160014432 | 160008916 | 1.52 | 96.1 | Neo-adjuvant (N) | 2018-04-08 | 2018-04-22 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101285374 |
| 160014507 | 160008917 | 1.71 | 96.4 | null | 2017-02-08 | 2017-02-23 | EW EuroEwing 2012 Arm B IE | N | N | VINORELBINE | 100233488 |
| 160014575 | 160008918 | 0 | 61.8 | Palliative (P) | 2017-10-03 | 2017-10-10 | GemCarbo Days 1+8 | N | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100932501 |
| 160014581 | 160008919 | 1.74 | 80 | Curative (C) | 2018-03-14 | 2018-03-24 | Doxorubicin + Olaratumab | N | N | TRIAL | 100957985 |
| 160014624 | 160008920 | null | null | Palliative (P) | 2016-07-23 | 2016-07-23 | Trial Unspecified | null | null | BEVACIZUMAB + CARBO + PACLITAXEL | 100917785 |
| 160014654 | 160008921 | 1.81 | 14.2 | Palliative (P) | 2019-04-12 | 2019-04-24 | IVADo | 02 | N | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 101142774 |
| 160014673 | 160008922 | null | null | Palliative (P) | null | 2016-04-27 | Enzalutamide | N | null | CARBOPLATIN + ETOPOSIDE | 101393883 |
| 160014722 | 160008923 | 1.65 | null | Palliative (P) | 2018-11-15 | 2018-11-15 | OCTREOTIDE | 02 | null | DOXORUBICIN + OLARATUMAB | 100901395 |
| 160014779 | 160008924 | 0 | 18.3 | Neo-adjuvant (N) | 2019-07-04 | 2019-07-04 | Vinorelbine (oral) | 02 | N | GEMCITABINE | 100696816 |
| 160014825 | 160008925 | 1.68 | 104 | Palliative (P) | 2017-03-05 | 2017-03-09 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100289358 |
| 160014891 | 160008926 | 1.71 | 96.6 | Neo-adjuvant (N) | 2017-09-06 | 2017-09-25 | Doxorubicin + Ifosfamide | N | null | VIDE | 101812067 |
| 160014945 | 160008927 | 1.65 | 118 | Palliative (P) | 2020-04-22 | 2020-04-30 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101660218 |
| 160014982 | 160008928 | 1.83 | 72.6 | Adjuvant (A) | 2019-03-01 | 2019-03-01 | Enzalutamide | N | null | EW EUROEWING 2012 ARM A VIDE | 100713103 |
| 160015058 | 160008929 | 1.55 | null | Neo-adjuvant (N) | 2018-07-10 | 2018-07-21 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101134529 |
| 160015119 | 160008930 | 0 | 35.1 | Disease modification (D) | 2019-06-16 | 2019-06-30 | Doxorubicin + Olaratumab | 02 | N | EW EUROEWING 2012 ARM A VIDE | 101564654 |
| 160015135 | 160008931 | 1.75 | 71.1 | Palliative (P) | 2019-06-25 | 2019-06-28 | Doxorubicin + Olaratumab | 02 | N | EW EUROEWING 2012 ARM B VDC | 100858738 |
| 160015293 | 160008932 | 0 | 0 | Palliative (P) | 2017-11-16 | 2017-11-20 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101863393 |
| 160015356 | 160008933 | 1.74 | 62.1 | null | 2018-07-08 | 2018-07-08 | EW EuroEwing 2012 Arm A VIDE | 02 | null | IVA | 101248320 |
| 160015366 | 160008934 | 1.67 | 62.5 | Palliative (P) | 2019-03-04 | 2019-03-12 | IPILIMUMAB + NIVOLUMAB | N | N | ICON8B TRIAL | 101057345 |
| 160015376 | 160008935 | 1.76 | 65 | Palliative (P) | 2019-04-06 | 2019-04-19 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | EW EUROEWING 2012 ARM B VDC | 101742479 |
| 160015510 | 160008937 | 1.8 | 147 | Palliative (P) | 2019-05-11 | 2019-05-20 | Doxorubicin 75mg/m2 | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101243872 |
| 160015547 | 160008938 | 0 | 28 | Palliative (P) | 2016-09-06 | 2016-09-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101260596 |
| 160015559 | 160008939 | 1.78 | 110.3 | Palliative (P) | 2019-06-20 | 2019-06-29 | STS Rhabdomyosarcoma RMS 2005 IVAVV | N | N | LIPOSOMAL DOXORUBICIN | 100215341 |
| 160015614 | 160008940 | 1.68 | 62.6 | null | 2014-05-08 | 2014-06-07 | Bevacizumab+Carbo+Pacliaxel | 02 | null | LIPOSOMAL DOXORUBICIN | 100093550 |
| 160015644 | 160008941 | 1.68 | 58.7 | Palliative (P) | null | null | Cisplatin + Pemetrexed | N | null | CISPLATIN + PEMETREXED | 101691294 |
| 160015769 | 160008942 | 1.77 | 73.2 | null | 2019-02-04 | 2019-02-20 | GemCarbo Days 1+8 | 2 | N | DOXORUBICIN + OLARATUMAB | 101344878 |
| 160015907 | 160008943 | 1.7 | 72.2 | Palliative (P) | 2017-02-15 | 2017-02-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101523408 |